Meet the Team
Our team combines a deep level of scientific and industry experience with a strong commitment to making an impact and saving lives with the innovative work we do to address infectious diseases.
Ted Schroeder joined Nabriva Therapeutics plc in July 2018. During the last 30 years, he has been focused on drug development and commercialization in both large and small pharmaceutical companies. Most recently, Ted served as president, chief executive officer and director of Zavante Therapeutics until its acquisition by Nabriva Therapeutics in 2018. Ted co-founded Cadence Pharmaceuticals in 2004 and previously held leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals and earlier in his career, Bristol-Myers Squibb. He currently serves on the board of Cidara Therapeutics (Nasdaq: CDTX), Otonomy (Nasdaq: OTIC) and Collegium Pharmaceutical (Nasdaq: COLL). He is a former chair of BIOCOM, the Southern California life sciences trade association and in 2014, he was named the EY Entrepreneur of the Year for the San Diego region and was listed as a national finalist. He received a bachelor’s degree in management from Rutgers University.
Robert Crotty joined Nabriva Therapeutics in June 2017. He has over a decade of experience in the pharmaceutical and biopharmaceutical industries, most recently as Vice President, General Counsel, Chief Compliance Officer, and Secretary at Vernalis Therapeutics, Inc. Robert has a broad legal skill set with experience in corporate governance, securities filings, financing, business development, corporate law, and commercial compliance. Previously, he worked in the life sciences industry with positions at Dendreon Corp., NPS Pharmaceuticals, and ImClone Systems Inc. After law school, Robert worked at two law firms, Morgan, Lewis & Bockius and Norton Rose Fulbright.
Mr. Crotty obtained his law degree from the University of Pennsylvania and his undergraduate degree from Princeton University.
Steven Gelone joined Nabriva Therapeutics in December 2014. Over the past 20 years, Steve has been involved in all stages of drug development and commercialization. He has served as Head of Clinical Research and Development at Spark Therapeutics, as well as Vice President of Development at ViroPharma Inc., (now Shire). Previous roles include leadership positions with GSK, Vicuron Pharmaceuticals, and Temple University Schools of Pharmacy and Medicine. He has a Bachelor of Sciences and Doctorate in Pharmacy degree from Temple University in Philadelphia.
Francesco Maria Lavino joined Nabriva Therapeutics in July 2017, bringing nearly two decades of pharmaceutical sales and marketing experience to his role. The last half of his career has been focused on anti-infective medications administered primarily in the hospital setting. He most recently served as AVP, Global Brand Leader Anti-Infective Portfolio at Merck & Co. Inc. (known as MSD outside the United States), where he was responsible for the development and implementation of the global marketing strategy for the whole Merck anti-bacterial portfolio. Prior to this role, Francesco was Vice President of International Marketing for the Anti-Infectives Portfolio at Cubist Pharmaceuticals, held various roles at Merck including global brand leadership for the company’s antifungal portfolio and positions in marketing and sales, both at regional and country levels. Francesco began his career in pharmaceutical sales at UCB Pharma and 3M in Italy. He has a BA in Pharmacy from the Federico II University of Napoli, Italy and an MBA from SDA Bocconi School of Management in Milan, Italy.
Jennifer Schranz, MD, joined Nabriva Therapeutics in March 2018 and leads their clinical development and medical affairs teams. She has nearly two decades of experience in clinical development and medical affairs working with small molecules, biologics, and vaccines in both small and large pharmaceutical companies. Dr. Schranz was most recently the rare disease global development team lead at Shire plc where she oversaw clinical development, regulatory and life cycle management activities for the company’s hereditary angioedema franchise. She was previously vice president, clinical research at ViroPharma and prior to that vice president clinical research at Cempra. Earlier in her career, she held positions of increasing responsibility in clinical development and medical affairs at several pharmaceutical companies, including Wyeth (now Pfizer), Vicuron, GlaxoSmithKline, and Merck & Co. Inc.. Dr. Schranz earned an M.D. from the University of Toronto, where she completed her internal medicine training and was a fellow in infectious diseases.
Gary Sender has over 25 years of financial leadership experience in the pharmaceutical and biopharmaceutical industries, most recently as CFO and Executive Vice President at Synergy Pharmaceuticals. From 2009 to 2015,
Mr. Sender served as Senior Vice President, Finance at Shire plc. supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. He was responsible for financial management and support of all commercial areas of Shire’s $6 billion Specialty Pharmaceutical and Rare Disease businesses, with an emphasis on resource allocation, financial forecasting, business cases, and M&A. Prior to joining Shire, he was the founding CFO of Tengion, a biotechnology company in the field of Regenerative Medicine. Mr. Sender spent 15 years in a number of leadership roles within Merck, including Investor Relations, M&A Finance, Treasury and Divisional Financial Management. Mr. Sender holds a bachelor’s degree in Finance and Information Systems from Boston University and an MBA in Industrial Administration with a concentration in Finance from Carnegie-Mellon University.
SV LIFE SCIENCES
Daniel Burgess – Chairman
Mr. Burgess is Venture Partner at SV Life Sciences. Previously, he was President and CEO of Rempex Pharmaceuticals, an antibiotics company he co-founded in 2011 and subsequently sold to The Medicines Company in 2013. Prior to this, Mr. Burgess was President and CEO of Mpex Pharmaceuticals, a company that advanced an inhaled antibiotic for cystic fibrosis into Phase 3 before it was acquired by Aptalis Inc. in 2011. Previously, he served as COO and CFO of Hollis-Eden Pharmaceuticals, a public biotechnology company focused on biodefense, infectious diseases, and immune system disorders. Mr. Burgess also spent 10 years at Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Ltd), where he held a variety of executive-level positions with responsibility for overall finance for the company. He began his career at Castle & Cooke and Smith Barney, Harris Upham & Co. Mr. Burgess is Chairman of Atox Bio and is a board member of Cidara Therapeutics, Arsanis, Arbutus Biopharma Corp., and Pulmocide. He received a BA in Economics from Stanford University and an MBA from Harvard Business School.
NABRIVA THERAPEUTICS PLC.
Mr. Schroeder joined Nabriva Therapeutics plc in July 2018. During the last 30 years, he has been focused on drug development and commercialization in both large and small pharmaceutical companies. Most recently, Ted served as president, chief executive officer and director of Zavante Therapeutics until its acquisition by Nabriva Therapeutics in 2018. Ted co-founded Cadence Pharmaceuticals in 2004 and previously held leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals and earlier in his career, Bristol-Myers Squibb. He currently serves on the board of Cidara Therapeutics (Nasdaq: CDTX), Otonomy (Nasdaq: OTIC) and Collegium Pharmaceutical (Nasdaq: COLL). He is a former chair of BIOCOM, the Southern California life sciences trade association and in 2014, he was named the EY Entrepreneur of the Year for the San Diego region and was listed as a national finalist. He received a bachelor’s degree in management from Rutgers University.
Ms. Bourdow has been President, Chief Executive Officer, and a member of the Trevena Board of Directors since October 2018. She has served in various senior positions at Trevena since May 2015. She joined Trevena as Chief Commercial Officer and was appointed Executive Vice President and Chief Operating Officer in January 2018. Prior to joining Trevena, she was Vice President of Marketing at Cubist Pharmaceuticals, Inc., until its acquisition by Merck & Co., in January 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for five acute care hospital pharmaceuticals totaling over $1 billion in annual revenues. Before joining Cubist, she served for more than 20 years at Merck & Co., Inc., where she held positions across several therapeutic areas including anti-infectives, acute heart failure, and pain. Ms. Bourdow holds a BA degree from Hendrix College and earned her MBA from Southern Illinois University.
NABRIVA THERAPEUTICS, PLC
Colin Broom joined Nabriva Therapeutics in August 2014. Over the past 30 years, he has been involved in all stages of drug development and commercialization. Most recently, he served as Chief Scientific Officer at ViroPharma Inc., (now Shire). Previous positions have included a range of leadership roles with Amgen, Hoechst Marion Roussel (now Sanofi), SmithKline Beecham, and Glaxo (now GlaxoSmithKline). He has a BS in Pharmacology from University College, London and a Bachelor of Medicine and Surgery degree from St. George’s Hospital Medical School, London. He is a member of the UK Royal College of Physicians and a fellow of the Faculty of Pharmaceutical Medicine.
Formerly of ZALICUS, INC.
Mark Corrigan, MD
Dr. Corrigan is former President and CEO of Zalicus, Inc. Previously, he was Executive Vice President of Research and Development at the specialty pharmaceutical company Sepracor Inc. He also spent 10 years with Pharmacia & Upjohn, most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Before entering the healthcare industry, Dr. Corrigan was in academic research at the University of North Carolina at Chapel Hill School of Medicine, where he maintains a faculty appointment as Adjunct Professor in the Psychiatry Department. Dr. Corrigan served on the board of directors for Cubist Pharmaceuticals and Avanir Pharmaceuticals prior to their acquisitions by Merck and Otsuka Holdings, respectively, and he served as chairman of EPIRUS Biopharmaceuticals’ board. Dr. Corrigan holds an MD from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.
TALBOT ADVISORS LLC
George Talbot, MD, FACP, FIDSA
Dr. Talbot, an infectious diseases physician trained at the University of Pennsylvania Medical Center, began his pharmaceutical career in anti-infective drug development at Rhone-Poulenc Rorer, subsequently Aventis. He founded his consultancy firm, Talbot Advisors LLC, in 2000. Dr. Talbot later served as Executive Vice President/ Chief Medical Officer of Cerexa Inc. (purchased by Forest Laboratories) and worked closely with the development teams at Calixa Therapeutics (acquired by Cubist Pharmaceuticals) and Durata Therapeutics (purchased by Actavis Plc). He was a founding member of IDSA's Antimicrobial Availability Task Force ("Bad Bugs, No Drugs"), currently sits on IDSA’s Antimicrobial Resistance Committee, was a committee member of the CLSI (previously NCCLS), and is past co-chair of the ABSSSI/CABP and HABP/VABP Clinical Trial Endpoint Development Project Teams at the Biomarkers Consortium of the Foundation of the National Institutes of Health. He has co-authored more than 100 publications in peer-reviewed scientific journals.
Charles Rowland, Jr., CPA
Mr. Rowland is a member of the board of directors of Blueprint Pharmaceuticals and was most recently the CEO of Aurinia Pharmaceuticals. He was previously the Vice President and CFO of ViroPharma Inc., until it was acquired by Shire plc in January 2014. He has over 35 years of diversified experience in pharmaceutical operations and all areas of finance and accounting. Prior to joining ViroPharma in 2008, he was Executive Vice President and Chief Financial Officer for Endo Pharmaceuticals as well as its interim Co-CEO. He held positions of increasing responsibility at Biovail Corp., Breakaway Technologies, Pharmacia Corp., Novartis AG, and Bristol-Myers Squibb Co. He holds an MBA from Rutgers University and a BS in Accounting from Saint Joseph's University.
Mr. Webster is CFO of the gene therapy company Spark Therapeutics. He was previously Senior Vice President and CFO of Optimer Pharmaceuticals, Inc., a biotechnology company developing specialty drugs to treat gastrointestinal infections and related diseases, until its acquisition by Cubist Pharmaceuticals. Prior to this, Mr. Webster served as Senior Vice President and CFO of Adolor Corp., also acquired by Cubist. Previously, Mr. Webster served as Managing Director, Investment Banking Division, Health Care Group for Broadpoint Capital Inc. (formerly First Albany Capital). He also was co-founder, President, and CEO of Neuronyx, Inc., a biopharmaceutical company. Previously,
Mr. Webster held positions of increasing responsibility, including Director, Investment Banking Division, Health Care Group, for PaineWebber Inc. Mr. Webster holds an AB in Economics cum laude from Dartmouth College and an MBA in Finance from The Wharton School of the University of Pennsylvania.
© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland